Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ligand Pharmaceuticals reports stellar Q4 earnings and growth prospects

Ligand Pharmaceuticals demonstrated robust financial performance in Q4 2022, driven by strong royalty revenue growth and strategic initiatives.
While facing challenges in cost optimization and label expectations, Ligand's focus on operational efficiency and growth opportunities positions it well for the future.
With a solid financial foundation, a diverse portfolio of assets, and a commitment to strategic growth, Ligand is poised for continued success and value creation.

Ligand Pharmaceuticals excels in Q1, eyes growth through strategic assets

Ligand Pharmaceuticals delivered robust Q1 results, positioning itself for continued growth and financial stability.
The company's strategic focus on high-quality assets, diversification, and efficient deal execution underscores its commitment to driving value for investors.
Despite market challenges, Ligand remains optimistic, leveraging opportunities in the biopharmaceutical sector to sustain growth and enhance shareholder value.

Ligand Pharmaceuticals excels in Q2, eyes strategic growth opportunities

Ligand Pharmaceuticals delivered a robust performance in Q2 2023, driven by strong revenue growth and strategic financial moves.
While facing challenges in contract revenue and competitive markets, Ligand's focus on key products and acquisitions signals resilience and adaptability.
Opportunities lie in expanding revenue streams, navigating market dynamics, and leveraging FDA developments for future growth.

Ligand Pharmaceuticals reports robust Q3 earnings and strategic investments

Ligand Pharmaceuticals showcased strong financial performance, strategic investments in late-stage products, and a focus on revenue growth and portfolio management. Despite challenges in clinical trials and market estimations, the company's emphasis on growth and investor engagement presents opportunities for future success.

Ligand Pharmaceuticals reports robust Q4 earnings and strategic growth moves

Ligand Pharmaceuticals showcased a strong financial performance in Q4 2023, with strategic business streamlining and portfolio enhancements driving growth. Despite supply constraints related to a predecessor product, successful collaborations have ensured manufacturing readiness for key products like Rylaze. The company's diversified portfolio and strong partnerships position it well for continued growth and shareholder returns in 2024.

Ligand Pharmaceuticals reports robust Q1 performance and strategic investments

Ligand Pharmaceuticals shows strong financial performance and growth potential, supported by strategic partnerships and key developments in their portfolio.
While facing challenges like upcoming generic competition and revenue uncertainty from recent deals, the company remains focused on long-term growth.
Opportunities lie in projected revenue and EPS growth, market expansion for Filspari, and continued interest in licensing for revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q2 2019 Results - Earnings Call Transcript

Ligand (LGND) delivered earnings and revenue surprises of 11.48% and 9.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Surpasses Q2 Earnings and Revenue Estimates

Calix

CNX Resources

Audacy Inc

J.B. Hunt Transport Services

Ring Energy

Insider buying could be a great bullish indicator for a stock. Insiders sell for many reason, but they only buy for one -- and maybe you should buy too.

7 Stocks That Insiders Are Buying

Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

Ligand Inks Oncology Drug Discovery Deal With PhoreMost

CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 1,000 shares of LGND on 05/31/2019 at an average price of $108.2 a share.

Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $108,200 of Shares

Ligand (LGND) first-quarter earnings and sales decrease year over year.

Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down

Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q1 2019 Results - Earnings Call Transcript

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand Pharmaceuticals (LGND) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie

Celgene

Exelixis

Vertex Pharmaceuticals

Looking for potential winning biotech stocks? These five check off all the boxes for investors.

5 Top Biotech Stocks to Buy in 2019

Ligand Pharmaceuticals Partner Seelos Therapeutics, Inc. recently achieved a major milestone by going public via a reverse merger with Apricus Biosciences, Inc.

Ligand Pharmaceuticals Partner Sellos Therapeutics Shares Set To Soar As Value Of Its Potential Billion-Dollar Pipeline Is Realized

Ligand Pharmaceuticals Partner Seelos Therapeutics Shares Set To Soar As Value Of Its Potential Billion-Dollar Pipeline Is Realized

Amarin Corporation Plc

AstraZeneca

Jazz Pharmaceuticals

Leap Therapeutics

Lexicon Pharmaceuticals

PhaseBio Pharmaceuticals Inc

Roche Holding AG

SAGE Therapeutics

Strongbridge Biopharma

Sanofi

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand (LGND) Down 9.1% Since Last Earnings Report: Can It Rebound?

News for Ligand Pharmaceuticals Stock (LGND)